Suppliers / Sanofi

Sanofi

France SNY 29 employees Updated 9 July 2026

Sanofi is an API and finished-dose manufacturer based in France. It holds 11 active US drug master files across a filed portfolio of 11 molecules. Its filings concentrate with AIFA (IT), Health Canada and US FDA. Its GMP standing is certified by ANSM (FR), MFDS (Korea) and EMA, among 11 authorities. Its most recent recorded inspection, by US FDA, closed on 13 June 2025 as VAI.

11
active US DMFs
0
valid CEPs
12
registered plants
2,376
filings across 33 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
0 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 13 June 2025 VAI US FDA
  • 2 August 2024 VAI US FDA
  • 21 June 2024 NAI US FDA
  • 22 April 2023 VAI US FDA
  • 20 May 2022 VAI US FDA
  • 18 November 2021 VAI US FDA
  • 1 November 2019 NAI US FDA
  • 15 February 2019 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Ridgefield, United Arab Emirates Not on file
Scoppito, United Arab Emirates Not on file
Le Trait, United Arab Emirates Not on file
Cedex, United Arab Emirates Not on file
Tours, United Arab Emirates Not on file
Maison Alfort Cedex, United Arab Emirates Not on file

6 further sites are on record.

What they file, and where

Molecule Regulators Docs
Alfuzosin US FDA 1
Avanafil US FDA 1
Cabazitaxel US FDA 1
Chlorpromazine US FDA 1
Clopidogrel US FDA 1
Cromoglicic Acid US FDA 1
Dronedarone US FDA 1
Irbesartan US FDA 1
Meglumine US FDA 1
Promethazine US FDA 1
Show all 11 molecules on file
Zolpidem US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
AIFA (IT) 1,082 None
Health Canada 210 None
US FDA 173 3
INFARMED (PT) 171 None
EMA 158 6
DIGEMAPS (DO) 140 None
ANSM (FR) None 212
MFDS (Korea) None 8
EAEU_EEC None 5
CDSCO (India) None 4
HSA (SG) None 4
SAHPRA (ZA) None 3
MHRA (UK) None 3
ANVISA (Brazil) None 3
MINPROMTORG (RU) None 1

Scale

Year Revenue Exports Destinations
2022 $1.4B Not reported Not reported

Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.

Comparing suppliers?

Choose your molecules and target markets. Sanofi comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 1 active litigation matter is on record.
  • One recent serious compliance event is on record.
  • The most recent inspection outcome was VAI, on 13 June 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Company filings
Revenue as reported